Setmelanotide vs Tesofensine
Head-to-head comparison of Setmelanotide and Tesofensine for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Setmelanotide | Tesofensine |
|---|---|---|
| Category | Metabolic / MC4R Agonist | Weight Loss / Reuptake Inhibitor |
| Mechanism | Setmelanotide is a selective MC4R agonist that re-establishes signaling in the hypothalamic leptin-melanocortin pathway. | Tesofensine inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing synaptic concentrations of all three monoamines. |
| Evidence Rating | A — FDA Approved | C — Phase II–III Clinical Trials |
| Clinical Status | FDA-approved (Imcivree, November 2020 for POMC/PCSK1/LEPR deficiency obesity; June 2022 for BBS obesity) | Phase 3 clinical trials (Saniona). Phase 2 completed with significant weight loss results. |
| Safety Profile | Skin hyperpigmentation: occurs in most patients due to MC1R agonism. Typically darkening of existing skin and nevi. Dermatologic monitoring recommended.; Spontaneous erections and sexual adverse effects: common in males due to central melanocortin signaling. Generally decrease over time. | Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses; Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea |
| Molecular Weight | ~1117.3 g/mol | ~397.5 g/mol |
| Half-Life | ~11 hours | N/A |
Overview
Setmelanotide and Tesofensine are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Setmelanotide — Mechanism & Evidence
Setmelanotide (brand name Imcivree) is a cyclic 8-amino-acid peptide (MW ~1117.3 g/mol) that acts as a melanocortin 4 receptor (MC4R) agonist. It was subsequently approved for Bardet-Biedl syndrome (BBS) in June 2022. Setmelanotide directly restores MC4R signaling downstream of the defective leptin-melanocortin pathway.
Key claims: Significant weight loss in POMC deficiency obesity; Effective in LEPR deficiency obesity; Reduces hyperphagia in Bardet-Biedl syndrome.
Tesamorelin 10mg
10mg
Tesofensine — Mechanism & Evidence
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.
Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.
Shared Research Applications
These peptides target different research areas. Setmelanotide focuses on Weight Management, Metabolic Health, while Tesofensine targets Weight Loss, Appetite Suppression.
Safety Considerations
Setmelanotide: Skin hyperpigmentation: occurs in most patients due to MC1R agonism. Typically darkening of existing skin and nevi. Dermatologic monitoring recommended. Spontaneous erections and sexual adverse effects: common in males due to central melanocortin signaling. Generally decrease over time. Depression and suicidal ideation: reported in trials; patients should be monitored for mood changes
Tesofensine: Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea Psychiatric effects reported: anxiety, mood changes (consistent with monoamine reuptake inhibitors)
Shop Research Peptides
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.